SIRT1 activator SRT3025 provides atheroprotection in ApoE⁻/⁻ mice by increasing hepatic LDL receptor by Miranda, Melroy Xavier
Zurich Open Repository and
Archive
University of Zurich
Main Library
Strickhofstrasse 39
CH-8057 Zurich
www.zora.uzh.ch
Year: 2015
SIRT1 activator SRT3025 provides atheroprotection in ApoE￿/￿ mice by
increasing hepatic LDL receptor
Miranda, Melroy Xavier
Abstract: 1. Summary (English version) Elevated levels of LDL-cholesterol play a crucial role in the
development of atherosclerosis. Concordantly, clearance of excess LDL-cholesterol from the blood stream
by hepatic LDL receptor (LDL-R) is known to provide atheroprotection. The NAD+-dependent deacety-
lase SIRT1 has been described to be protective in lipid dysfunction and to mediate beneficial effects of
caloric restriction, while its role in atherosclerosis remains controversial. To address this controversy
we studied the effects of pharmacological SIRT1 activation in two different models of atherosclerosis
- apolipoprotein E knockout (ApoE-/-) and LDL receptor knockout (LDL-R-/-) mice. ApoE-/- mice
fed a high-cholesterol diet (1.25% w/w) and supplemented with the SIRT1 activator, SRT3025 (400
mg/kg/d) for 12 weeks showed less atherosclerosis, and lower plasma levels of total cholesterol and
LDL-cholesterol as well as inflammatory cytokines IL-6 and MCP-1. Hepatic LDL-R and PCSK9 ex-
pression were increased with a reduction in secreted plasma PCSK9 levels. In vitro SRT3025 caused a
reduction in PCSK9 secretion with a similar SIRT1- dependent increase in LDL-R expression in AML12
hepatoma cells. In LDL-R-/- mice, the atheroprotective effects of SRT3025 observed in ApoE-/- mice
were abolished whereas the decrease in plasma levels of the inflammatory cytokines IL-6 and MCP-1 was
maintained. Our data provide evidence that SIRT1 activation is atheroprotective by reducing plasma
LDL-cholesterol levels through an increase in liver LDL-R expression and reduced PCSK9 secretion.
Our findings underline the potential of SIRT1 activation as a therapy against atherosclerosis. 1.2 Sum-
mary (German Version) Erhöhte Plasmaspiegel von LDL-Cholesterin sind ursächlich an der Entstehung
der Atherosklerose beteiligt. Eine Reduktion von überschüssigem LDL- Cholesterin aus dem Kreislauf
durch den hepatischen LDL-Rezeptor (LDL-R) wirkt hingegen atheroprotektiv. Die NAD+ - abhängige
Deacetylase SIRT1 wirkt protektiv in Lipidstörungen und vermittelt günstige metabolische Effekte der
Kalorien-Restriktion. Jedoch kamen verschiedene Studien zu unterschiedlichen Ergebnissen bezüglich der
Rolle von SIRT1 in der Arteriosklerose. In der vorliegenden Arbeit wurde daher in zwei Maus-Modellen
der Atherosklerose - Apolipoprotein E-Knockout (ApoE-/-) und LDL-Rezeptor- Knockout (LDL-R-/-
) - der Effekt einer pharmakologischen SIRT1-Aktivierung untersucht. ApoE-/- Mäuse, welche für 12
Wochen eine cholesterinreiche Diät (1,25% w / w) ergänzt durch den SIRT1 Aktivator SRT3025 (400
mg / kg / d) erhielten, entwickelten weniger Arteriosklerose und geringere Plasmaspiegel an Gesamt-
und LDL-Cholesterin, sowie der inflammatorischen Zytokine IL-6 und MCP-1. Die hepatische LDL-R
und PCSK9 Protein-Expression war erhöht, die Plasma-Spiegel von PCSK9 dagegen erniedrigt. In vitro
verursachte SRT3025 eine Verringerung der PCSK9 Sekretion und einen SIRT1-abhängigen Anstieg der
LDL-R-Expression in AML12 Zellen. Entsprechende Tierversuche in LDL-R- /- Mäusen zeigten einen
Verlust der atheroprotektiven Wirkung von SRT3025 mit einer Verringerung der entzündlichen Zytokine
IL-6 und MCP-1 im Plasma. Zusammenfassend zeigen unsere Daten, dass SIRT1-Aktivierung athero-
protektiv wirkt, vermittelt durch eine Reduktion von Plasma LDL- Cholesterin durch eine Erhöhung der
Leber LDL-R-Expression und die Reduktion der PCSK9 Sekretion. Unsere Ergebnisse unterstützen das
Potential der SIRT1-Aktivierung als potentielle Therapie gegen Arteriosklerose.
Posted at the Zurich Open Repository and Archive, University of Zurich
ZORA URL: https://doi.org/10.5167/uzh-164462
Dissertation
Published Version
Originally published at:
Miranda, Melroy Xavier. SIRT1 activator SRT3025 provides atheroprotection in ApoE￿/￿ mice by in-
creasing hepatic LDL receptor. 2015, University of Zurich, Faculty of Science.
2
SIRT1 activator SRT3025 provides atheroprotection in 
ApoE-/- mice by increasing hepatic LDL receptor 
Dissertation 
zur 
Erlangung der naturwissenschaftlichen Doktorwürde 
(Dr. sc. nat.) 
vorgelegt der 
Mathematisch-naturwissenschaftlichen Fakultät 
der 
Universität Zürich 
von 
Melroy Xavier Miranda 
aus 
Indien 
Promotionskomitee 
Prof. Dr. Dr. Michael O. Hottiger (Vorsitz) 
PD. Dr. Christian M. Matter MD (Leitung der Dissertation) 
Prof. Dr. Michael O. Hengartner 
Prof. Dr. Thomas A. Lutz 
Prof. Dr. Kristina Schoonjans 
!2
!Table&of&Contents&
&
1. Summary.................................................................................................................................5#7&1.1. Summary,in,English........................................................................................................5&1.2. Summary,in,German.......................................................................................................6&,
2. Abbreviations......................................................................................................................8#9,,
3. Introduction....................................................................................................................10#30,3.1. Atherosclerosis..............................................................................................................10,3.2. LDL#cholesterol,and,cardiovascular,disease....................................................12,3.3. Regulation,of,LDL#cholesterol,by,modulating,LDL,receptor.....................14,3.4. LDL,receptor,regulation by PCSK9........................................................................17,3.5. Caloric,restriction,and,sirtuins...............................................................................19,3.6. SIRT1,and,cellular,metabolism...............................................................................22,3.7. SIRT1,and,lipid,metabolism.....................................................................................23,3.8. SIRT1,and,cardiovascular,disease.........................................................................25,3.9. SIRT1,activators,in,animal,studies........................................................................283.10,SIRT1,activators,and,their,specificity.................................................................29,
4. Hypothesis,&aims&and&design.................................................................................31#33,4.1. Hypothesis.......................................................................................................................31,4.2. Specific,aims...................................................................................................................32,4.3. Experimental,design...................................................................................................33,,
3
!5. Results...............................................................................................................................34#54,5.1. Primary,publication....................................................................................................34,5.2. Contribution,to,other,published,articles...........................................................35,5.3. Primary,publication,paper.......................................................................................37,,
6. Perspectives...................................................................................................................55#63,6.1. SIRT1,activator,SRT3025,,atherosclerosis,and,lipid,dysfunction..........55,6.2. Role,of,sirtuins,in,the,regulation,of,PCSK9.......................................................56,6.3. SIRT1,,white,adipose,tissue,and,atherosclerosis...........................................57,6.4. Alternative,pathways,of,SIRT1,activation:,increasing,NAD+,levels.......59,6.5. Future,prospects..........................................................................................................63,,
7. References......................................................................................................................64#76,
8. Acknowledgements..........................................................................................................77,,
9. Credit&Points.........................................................................................................................78,,
10. &Curriculum&Vitae.........................................................................................................79-81,
4
1. Summary
1.1 Summary (English version) 
Elevated levels of LDL-cholesterol play a crucial role in the development of 
atherosclerosis. Concordantly, clearance of excess LDL-cholesterol from the 
blood stream by hepatic LDL receptor (LDL-R) is known to provide 
atheroprotection. The NAD+-dependent deacetylase SIRT1 has been described 
to be protective in lipid dysfunction and to mediate beneficial effects of caloric 
restriction, while its role in atherosclerosis remains controversial. 
To address this controversy we studied the effects of pharmacological 
SIRT1 activation in two different models of atherosclerosis - apolipoprotein E 
knockout (ApoE-/-) and LDL receptor knockout (LDL-R-/-) mice. ApoE-/- mice fed 
a high-cholesterol diet (1.25% w/w) and supplemented with the SIRT1 
activator, SRT3025 (400 mg/kg/d) for 12 weeks showed less atherosclerosis, 
and lower plasma levels of total cholesterol and LDL-cholesterol as well as 
inflammatory cytokines IL-6 and MCP-1. Hepatic LDL-R and PCSK9 
expression were increased with a reduction in secreted plasma PCSK9 levels. 
In vitro SRT3025 caused a reduction in PCSK9 secretion with a similar SIRT1- 
dependent increase in LDL-R expression in AML12 hepatoma cells. In LDL-R-/- 
mice, the atheroprotective effects of SRT3025 observed in ApoE-/- mice were 
abolished whereas the decrease in plasma levels of the inflammatory cytokines 
IL-6 and MCP-1 was maintained. 
Our data provide evidence that SIRT1 activation is atheroprotective by 
reducing plasma LDL-cholesterol levels through an increase in liver LDL-R 
expression and reduced PCSK9 secretion. Our findings underline the potential 
of SIRT1 activation as a therapy against atherosclerosis. 
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1.2 Summary (German Version) 
Erhöhte Plasmaspiegel von LDL-Cholesterin sind ursächlich an der Entstehung 
der Atherosklerose beteiligt. Eine Reduktion von überschüssigem LDL-
Cholesterin aus dem Kreislauf durch den hepatischen LDL-Rezeptor (LDL-R) 
wirkt hingegen atheroprotektiv. Die NAD+ - abhängige Deacetylase SIRT1 wirkt 
protektiv in Lipidstörungen und vermittelt günstige metabolische Effekte der 
Kalorien-Restriktion. Jedoch kamen verschiedene Studien zu unterschiedlichen 
Ergebnissen bezüglich der Rolle von SIRT1 in der Arteriosklerose. 
In der vorliegenden Arbeit wurde daher in zwei Maus-Modellen der 
Atherosklerose - Apolipoprotein E-Knockout (ApoE-/-) und LDL-Rezeptor-
Knockout (LDL-R-/-) - der Effekt einer pharmakologischen SIRT1-Aktivierung 
untersucht.  ApoE-/- Mäuse, welche für 12 Wochen eine cholesterinreiche Diät 
(1,25% w / w) ergänzt durch den SIRT1 Aktivator SRT3025 (400 mg / kg / d) 
erhielten, entwickelten weniger Arteriosklerose und geringere Plasmaspiegel 
an Gesamt- und LDL-Cholesterin, sowie der inflammatorischen Zytokine IL-6 
und MCP-1. Die hepatische LDL-R und PCSK9 Protein-Expression war erhöht, 
die Plasma-Spiegel von PCSK9 dagegen erniedrigt. In vitro verursachte 
SRT3025 eine Verringerung der PCSK9 Sekretion und einen SIRT1-
abhängigen Anstieg der LDL-R-Expression in AML12 Zellen. Entsprechende 
Tierversuche in LDL-R-/- Mäusen zeigten einen Verlust der atheroprotektiven 
Wirkung von SRT3025 mit einer Verringerung der entzündlichen Zytokine IL-6 
und MCP-1 im Plasma. 
Zusammenfassend zeigen unsere Daten, dass SIRT1-Aktivierung 
atheroprotektiv wirkt, vermittelt durch eine Reduktion von Plasma LDL-
Cholesterin durch eine Erhöhung der Leber LDL-R-Expression und die 
6
Reduktion der PCSK9 Sekretion. Unsere Ergebnisse unterstützen das 
Potential der SIRT1-Aktivierung als potentielle Therapie gegen Arteriosklerose. 
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!2. Abbreviations
AML12 Alpha mouse liver 12 
ApoB100 Apolipoprotein B-100 
ApoE Apolipoprotein E 
BODIPY FL Boron-dipyrromethene flourophore 
CD38 Cluster of differentiation 38 
CD68 Cluster of differentiation 68 
CDK5 Cyclin-dependent kinase 5 
CHD Coronary heart disease 
CR Caloric restriction 
EGF Epidermal growth factor 
eNOS Endothelial nitric oxide synthase 
FH Familial hypercholesterolemia 
FOXO Forkhead Box O 
HDL-cholesterol High-density lipoprotein cholesterol 
HMGCoA 3-hydroxy-3-methylglutaryl Coenzyme A 
IL-6 Interleukin 6 
LDL Low-density lipoprotein 
LDL-cholesterol Low-density lipoprotein cholesterol 
LDL-R  Low-density lipoprotein receptor 
LXR Liver X receptor 
MCP-1 Monocyte chemo-attractant protein 1 
mmLDL minimally modified LDL 
oxLDL oxidized LDL 
8
!NA Nicotinic acid 
NAD Nicotinamide adenine dinucleotide 
NAM Nicotinamide 
NMN Nicotinamide mononucleotide 
NAMPT Nicotinamide phosphoribosyltransferase 
NR Nicotinamide riboside 
PARP Poly (ADP-ribose) polymerase 
PCSK9 Proprotein convertase subtilisin/kexin type 9 
PGC1α Peroxisome proliferator-activated receptor gamma 
coactivator 1-alpha 
PPARγ Peroxisome proliferator-activated receptor gamma 
p65 Nuclear Factor Kappa-B P65 Subunit 
Scr Scramble 
siRNA Small interfering RNA 
Sir2 Silent information regulator 2 
SIRT1 Sirtuin 1 (silent mating type information regulation 
2, homolog 1) 
STAC Sirtuin activating compound 
SREBP Sterol regulatory element binding protein 
TAMRA Carboxytetramethylrhodamine 
TNFα Tumor necrosis factor alpha 
VCAM-1 Vascular cell adhesion molecule 1 
VLDL-cholesterol Very low-density lipoprotein cholesterol 
WAT White adipose tissue 
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!3. Introduction
3.1 Atherosclerosis 
Atherosclerosis is a chronic progressive disease of the arteries and is the 
leading cause of death in developed countries. Atherosclerosis occurs when 
excess circulating low-density lipoprotein cholesterol (LDL-cholesterol) is 
oxidised and modified to accumulate in the arteries triggering local 
inflammation and plaque formation. Such an accumulation over time leads to 
an increase in plaque size, leading to narrowing of the coronary arteries. 
However, it is not the size of the plaque itself but rather its ability to rupture 
and form a blood clot (thrombus) that is deadly. Histological analyses have 
shown that more than 40% of the volume of most disrupted plaques were 
occupied by a necrotic lipid core, consisting of lipids, cholesterol crystals and 
necrotic debris and surrounded by a thin fibrous cap.1, 2 
In 1958 it was suggested that the pathological manifestation of plaque 
formation first occurred as an accumulation of fatty streaks.3 These early ‘fatty 
streak’ lesions consist of T cells and lipid-loaded macrophage-like foam cells.4 
The pathogenesis is initiated by endothelial dysfunction, which permits sub-
endothelial accumulation of excess low-density lipoprotein (LDL) particles 
containing cholesterol.5 The retained subendothelial LDL particles are 
susceptible to oxidative stress and transform into so-called oxidized LDL 
(oxLDL) or minimally modified LDL (mmLDL) by yet unknown mechanisms. 
10
!Figure 1. Formation of fatty streaks during atherosclerosis. Excess LDL-
cholesterol accumulates within the intima of the endothelium leading to 
endothelial activation and cytokine release. In the intima, these LDL particles 
are oxidized to form mmLDL or oxLDL. Macrophages ingest the oxLDL by 
scavenger receptors (CD36, SR-A) and accumulate to form foam cells. 
OxLDL is toxic to the cells and further causes the release of cytokines and 
chemokines from the endothelium, which increases the recruitment of 
monocytes leading to the formation of ‘fatty streaks’. (Adapted from 
Christopher K.  Glass, Joseph L.  Witztum, Cell, 2001) 
High levels of mmLDL or oxLDL trigger endothelial cells to express 
adhesion molecules and release chemokines, facilitating the infiltration and 
activation of macrophages.6 These activated macrophages phagocytise 
11
!oxLDL or mmLDL to form foam cells and fatty streaks beneath the 
endothelium. The excess oxidized lipid accumulation over time leads to the 
necrosis of foam cells and enhanced inflammation, thus leading to the 
formation of complex lesions. Since excess LDL-cholesterol is the main 
protagonist, lowering plasma LDL-cholesterol has evolved as an important 
therapy for treatment and prevention of atherosclerosis. 
3.2 LDL-cholesterol and cardiovascular disease 
Lipoprotein particles function as the main carriers of lipids in plasma. Low-
density lipoprotein is one of five major groups of lipoproteins and is the most 
abundant cholesterol transporter in the human body. Unlike other lipoproteins 
(chylomicrons, very low-density lipoprotein, intermediate-density lipoprotein 
and high-density lipoprotein), due to its composition, LDL is highly susceptible 
to oxidation. An LDL particle is composed of tightly bundled cholesterol, 
surrounded by a hydrophilic surface layer of phospholipid, and a hepatic 
sourced ApoB100 protein that adds to its stability. The core of the particle 
consists of esterified and non-esterified cholesterol and triglycerides. 
LDL-cholesterol has long been accepted as a major risk factor for the 
development of coronary heart disease (CHD) and is a well-validated target to 
reduce the risk of cardiovascular disease.7 Early studies showed that reducing 
cholesterol biosynthesis by inhibiting its rate-limiting enzyme, 3-hydroxy-3-
methylglutaryl Co-enzyme A (HMGCoA) reductase, reduces plasma LDL-
cholesterol levels.8 Thus the discovery of statins, which were potent inhibitors 
of HMGCoA reductase, ushered a new way to lower LDL-cholesterol. The 
12
!introduction of the first statin, Simvastatin, to patients in the Scandinavian 
Simvastatin Survival Study (4S) showed that lowering plasma cholesterol 
significantly reduced the risk of cardiovascular events in CHD patients.9 A 
1mmol/L reduction in LDL-cholesterol by statins was associated with a 20-
25% reduction in coronary risk.10 These findings proved that LDL-cholesterol 
lowering is an effective method to treat and prevent atherosclerosis. 
Figure 2. Cross-section of the low-density lipoprotein particle. The LDL 
particle is a lipophilic sphere consisting of an exterior polar surface made up 
of triacylglycerols and cholesteryl esters and an interior apolar core consisting 
of phospholipids and unesterified free cholesterol. The sphere is surrounded 
by an apolipoprotein B-100 (ApoB100) molecule. (Adapted from 
healthyprotocols.com) 
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!According to the PROVE-IT trial, intensive lipid lowering statin 
regimens provided greater protection against death or major cardiovascular 
events, than a standard regimen11, suggesting that continued lowering of LDL-
cholesterol beyond target levels would improve risk events in patients with 
cardiovascular disease. Hence it is logical to assume that further reducing 
LDL-cholesterol beyond current statin-levels via a non-statin strategy could 
markedly lower the residual risk of events in patients already receiving a 
statin. However, increasing the dosages of statins and intensive statin therapy 
may have its limitations due to various side-effects, like myalgia (increased 
liver enzymes),12 rhabdomyolysis (muscle breakdown),13 sexual dysfunction 
or in some cases a risk of diabetes.14, 15 Due to this the research and 
discovery of non-statin based LDL-cholesterol lowering drugs has attracted a 
lot of attention. 
3.3 Regulation of LDL-cholesterol by Modulating the LDL receptor 
Uptake of LDL by hepatic LDL receptors (LDL-R) is the primary mechanism 
for the clearance of circulating plasma LDL-cholesterol. Familial 
hypercholesterolemia (FH) is an autosomal dominant disease mainly caused 
by loss-of-function mutations in the gene encoding the LDL-R.16 FH is 
characterized by reduced LDL-cholesterol clearance and thus, an increased 
risk of atherosclerosis. To date over 1100 mutations in the LDL-R gene have 
been identified in FH patients. The study of FH has been instrumental in the 
discovery and study of LDL-R in cholesterol metabolism and its related 
diseases. FH is known to exist in 2 forms, the less severe heterozygous form 
14
!(when the mutation is present in only one of the two alleles of the gene) and 
the more severe homozygous form (when the mutation is present in both 
alleles of the gene).17 FH patients heterozygous for a mutation in the LDL-R 
gene have a 50% reduction in LDL-R, which causes a 2-fold increase in the 
number of LDL particles in blood from birth.18 Similarly, FH patients 
homozygous for a mutation in the LDL-R gene have a LDL-cholesterol 
concentration in the range of 200 mg/dL to 700 mg/dL. In 1974, the lack of 
uptake of radiolabeled LDL – 125Iodine-LDL in FH homozygote fibroblasts 
compared to normal fibroblasts, and the localisation of these radiolabeled LDL 
on the surface of normal fibroblasts led to the discovery of LDL-R.19 Brown 
and Goldstein, who pioneered this study, further showed that the release of 
LDL from radioactive 125I-LDL in normal cells caused the suppression of not 
only, 3-hydroxy-3-methylglutaryl CoA reductase (HMGCoA reductase) gene, 
the rate limiting enzyme for cholesterol synthesis, but also the LDL-R gene. 
Such studies highlighted the critical importance of LDL-R in the metabolism 
and regulation of plasma cholesterol. 
LDL-R is a transmembrane protein, 839 amino acids in length and 
consisting of 5 main domains, namely, the LDL-R repeat domain, the 
epidermal growth factor (EGF) repeat domain, O-linked glycosylation domain, 
transmembrane domain and the cytoplasmic domain.20 The interaction 
between the LDL-R and circulating LDL is electrostatic in nature, with the 
acidic residues in the LDL-R binding domain interacting with the basic 
residues of the ligand – apoB100.21 LDL-R is regulated by the transcription 
factor - sterol regulatory element binding protein (SREBP).22 Low levels of 
15
!intracellular sterols cause a series of molecular events that cause the 
transcription factor to localise to the nucleus.23 There are two genes encoding 
SREBP, with three different isoforms – SREBP1a, SREBP1c and SREBP2.24 
While SREBP1a and SREBP1c are involved in fatty acid metabolism, 
SREBP2 is the transcription factor mainly involved in cholesterol biosynthesis 
and metabolism. SREBP2 is the main transcription factor responsible for the 
transcription of HMGCoA reductase and LDL-R gene.22 When intracellular 
lipids are low, the N-terminal of SREBP2 binds to sterol regulatory elements in 
the LDL-R promoter causing an increase in LDL-R expression,25 which lead to 
an increase in surface-bound LDL-R expression. The LDL-R recognises the 
binding ligand, ApoB100, present on LDL particle through the LDL-R repeat 
domain. Recognition of the ApoB100 at neutral pH causes the internalisation 
of the LDL-LDL-R complex to form clathrin-coated vesicles.26 These coated 
vesicles disperse into the endosome, in which the acidic pH of the endosome 
activates the release of internalized ligands from the receptor through the 
EGF-repeat domain. While the released ligands travel to the lysosome for its 
lipid content, the LDL-R recycles back to the cell surface. Thus LDL-R 
continues to take up circulating LDL-cholesterol, until excess internalised 
cholesterol causes a reduction in LDL-R transcription by inhibiting SREBP2. 
Another mechanism for cells to regulate LDL-R expression is through 
proprotein convertase subtilisin/kexin type 9 (PCSK9). PCSK9 is a secreted 
chaperone that binds to cell-bound LDL-R in the presence of LDL-cholesterol 
and after internalisation of the complex, targets it for lysosomal degradation. 
16
!Figure 3. The role of PCSK9 in regulating expression of LDL-R. Secreted 
PCSK9 binds to membrane-bound LDL-R. A complex of LDL-cholesterol, 
LDL-R and PCSK9 undergoes clathrin-mediated endocytosis and 
subsequently is degraded in the lysosome. (Adapted from Catapano A.L and 
Papadopoulos N. Atherosclerosis, 2013). 
3.4 LDL-R regulation by PCSK9 
Proprotein convertase subtilisin/kexin type 9 is a member of the mammalian 
subtisilin family of proprotein convertases.27 It is a 72-kDa chaperone 
predominantly expressed in the liver, intestine and kidney. PCSK9 contains 
four domains – an N-terminal signal domain, a prodomain, a catalytic domain 
and a cysteine-rich C-terminal domain. The precursor of PCSK9 undergoes 
autocatalytic cleavage of the 14-kDa prodomain in the endoplasmic reticulum, 
to form an active PCSK9 protein. Although the prodomain undergoes 
17
!cleavage, it does not detach from the active protein, but blocks its catalytic 
domain allowing PCSK9 to function as a chaperone.  The active form of 
PCSK9 is then secreted into the plasma where it binds to the EGF domain of 
cell surface-bound LDL-R, in the presence of bound LDL-cholesterol. 
Internalised LDL-cholesterol-LDL-R-PCSK9 complex is then dispensed to the 
lysosome for degradation, thus preventing the recycling of LDL-R. Patients 
with gain-of-function mutations in PCSK9 have a 5- to 30-fold increased 
affinity for LDL-R compared to healthy subjects, thus having higher plasma 
LDL-cholesterol.28 In line with this, patients with loss-of-function mutations in 
PCSK9 have lower levels of plasma LDL-cholesterol.29 
Patients with gain-of-function mutations in PCSK9 have low sensitivity 
to statins with a predisposition to early onset atherosclerotic disease.30 In 
addition to regulating LDL-R and HMGCoA reductase expression, the 
transcription factor SREBP2 is also responsible for the expression of PCSK9. 
Since SREBP2 is the common the transcription factor for all three genes, the 
expression of these proteins are known to be interdependent. Decreased 
cholesterol levels or pharmacological inhibition of HMGCoA reductase by 
statins activates SREBP2 transcriptional activity, which not only leads to an 
increase in LDL-R expression but also PCSK9 expression.31 Consequently, 
statins increase plasma PCSK9 levels in a dose-dependent manner, thus 
limiting the LDL-cholesterol lowering effect of statins by an increase in 
PCSK9-mediated LDL-R degradation. These findings have stimulated the 
search for drugs that lower PCSK9 activity, serving as an adjunct to statins 
and/or as an alternative for treatment of atherosclerosis. 
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!3.5 Caloric restriction and sirtuins 
Caloric restriction (CR) refers to a metabolic state in which energy intake is 
reduced to below-normal levels, while being sufficiently high to avoid 
malnutrition. In 1935, Clive McCay for the first time described that restriction 
of calories without malnourishment prolongs mean and maximal lifespan in 
rats compared to ad libitum feeding.32 He later recommended that CR might 
be used as a model to study aging, however, little was known about the 
mechanism of caloric restriction itself33 Although Clive McCay and Otto 
Warburg described CR and the function of nicotinamide adenine dinucleotide 
(NAD+) in the same decade, it was not until more than half a century later that 
Imai et al. described the requirement of NAD+ for CR-dependent life-span 
extension in the yeast S. Cerevisiae.34 Thus a new era of research began 
addressing the modulation of NAD+ and NAD+-dependent enzymes in aging 
and age-related diseases. 
Coenzymatic activity of NAD+, coupled with stringent regulation of its 
bioavailability, makes it an ideal candidate for a metabolic sensor. This notion 
is partly supported by the fact that NAD+ functions as a substrate in key 
metabolic pathways such as the glycolytic pathway, respiratory chain and de 
novo biosynthesis of macromolecules.  Metabolic homeostasis involves a 
sensitive balance between energy intake, utilization and storage. The 
discovery of the yeast enzyme – Silent information regulator 2 (Sir2) as a 
NAD+-dependent deacetylase hinted at the importance of Sir2 in metabolic 
regulation.34, 35 Although Sir2 is a NAD+-dependent deacetylase, it does not 
19
!use NAD+ as a redox acceptor. Sir2 cleaves the NAD+ molecule during a 
deacetylation reaction, transferring the acetyl group to the ribose sugar, 
thereby producing O-acetyl-ADP-ribose and nicotinamide as by-products. The 
dependence of Sir2 activity on the cellular bioavailability of NAD+ and its high 
Km values for NAD+ alluded to a likely link between Sir2 activity and the 
metabolic state of the cell.35, 36 This led to studies investigating the 
relationship between aging and metabolic diseases involving Sir2 and Sir2-
related proteins. In mammals the highly conserved Sir2 protein and its 
orthologs belong to a family of proteins called ‘sirtuins’. 
Sirtuins are a family of highly conserved, ubiquitously expressed, 
NAD+-dependent class III histone deacetylase enzymes. They function mainly 
as metabolic sensors, translating changes in NAD+ levels into adaptive 
responses. They are now known to deacetylate a wide number of 
transcriptional regulators and thus oversee a plethora of metabolic processes. 
Based on their sequences, mammalian sirtuins are divided into four classes – 
SIRT1 to SIRT3 belong to class I, SIRT4 to class II, SIRT5 to class III and 
SIRT6 and SIRT7 to class IV.37 SIRT1 can shuttle between the nucleus and 
the cytoplasm, regulating gene expression by deacetylating nuclear 
transcription factors and cytoplasmic proteins,38 while SIRT2 is localized to 
the cytoplasm.39 SIRT3, SIRT4 and SIRT5 are mitochondrial proteins, 
whereas SIRT6 and SIRT7 are nuclear proteins, with SIRT7 mainly expressed 
in the nucleolus.40-42 Not all sirtuins have the same enzymatic activity. SIRT1, 
SIRT2, SIRT3, SIRT6 and SIRT7 are known to mainly function as deacetylase 
enzymes, while SIRT4 functions as an ADP-ribosylation enzyme. SIRT5 on 
20
!the other hand, not only has deacetylase activity but also desuccinylase and 
demalonylase activity. Of the seven mammalian sirtuins, SIRT1 was the first 
to be discovered and has been best characterized for its metabolic effects. 
Figure 4. The Sirtuin family of protein deacetylases. Sirtuins are NAD+-
dependent deacetylases that deacetylate multiple protein targets. In the 
deacetylation reaction, sirtuins utilize NAD+ as a cofactor and produce a 
deacetylated protein, nicotinamide (NAM) and 2’-O-acetyl-ADP ribose. NAM is 
recycled back to NAD+ by nicotinamide phosphoribosyltransferase (NAMPT). 
(Adapted from Oellerich M F, and Potente M. Circulation Research, 2012) 
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!3.6 SIRT1 and cellular metabolism 
SIRT1 deacetylates the ε-acetyl-lysine residues of its target protein. 
Consistent with its dual localisation in the nucleus and cytoplasm, SIRT1 
targets proteins in both cellular compartments. SIRT1 activity is generally 
accepted to increase with an increase in NAD+ level. Since the Km values of 
human SIRT1 are between 300-500μM,43 which is well within the 0.2 to 
0.5mM range of intracellular NAD+ level,44 cellular NAD+ level may be the rate-
limiting factor for SIRT1 enzymatic activity. Furthermore, although intracellular 
levels of NAD+ are difficult to assess, they rarely fluctuate more than 2-fold, 
thus being sufficiently capable of modulating SIRT1 activity.45, 46 Since both 
SIRT1 activity and NAD+ levels, are known to increase during exercise, fasting 
or caloric restriction, it highlights the tight link between SIRT1 and the 
regulation of energy metabolism.47, 48 
The importance of SIRT1 in normal development and physiology is 
highlighted by the fact that whole body deletion of SIRT1 is lethal. Inbred mice 
lacking both alleles of SIRT1 are smaller and die postnatal; outbred mice 
survive to adulthood and are sterile.49 Murine whole-body overexpression of 
SIRT1 has been shown to display features mimicking the benefits of caloric 
restriction. SIRT1 overexpression in mice protects against high-fat diet-
induced metabolic damage, insulin resistance and diabetes, with an increase 
in energy efficiency.50, 51 However, there are two major drawbacks of SIRT1 
overexpression studies. Firstly, higher SIRT1 expression may not necessarily 
result in increased SIRT1 activity; secondly, consistent overexpression of 
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!SIRT1 may not resemble normal metabolic processes observed during caloric 
restriction. Braidy et al supported these drawbacks by demonstrating that rats 
having lower NAD+ levels have a compromised level of SIRT1 activity.52 Thus 
demonstrating that the activity of SIRT1 can adequately increase only in the 
presence of sufficient quantities of its bioavailable substrate, NAD+, and not by 
solely overexpressing SIRT1 protein alone. Although SIRT1 was initially 
described as an enzyme that deacetylates mainly histones, it was later found 
to have many non-histone targets. p53 was the first non-histone target of 
SIRT1 to be discovered. SIRT1 deacetylates p53, inhibiting p53-mediated 
apoptosis, thus favouring cell repair and survival.53 Subsequently, SIRT1 was 
shown to deacetylate numerous targets, including transcription factors like 
NFκB, PGC1α, LXR and different FOXO isoforms.54-57 
3.7 SIRT1 and lipid metabolism 
Sirtuins modulate multiple aspects of cellular lipid metabolism in a number of 
different tissues like white adipose tissue (WAT), liver and skeletal muscle 
SIRT1 has been shown to have affect WAT in different ways. Mice placed on 
a high-fat diet, overexpressing SIRT1 or treated with SIRT1 activators, show a 
reduction in the increase of WAT mass.51, 58 SIRT1 gain of function mimics 
insulin-sensitizing function of PPARγ ligands in vivo.50 SIRT1 deacetylates 
PPARγ in WAT promoting browning of subcutaneous WAT, thus promoting 
energy expenditure over energy storage.59 Inhibition of SIRT1 in 3T3 L1 cells 
(an adipocyte differentiation model) promotes adipocyte differentiation while 
its overexpression blocks adipocyte differentiation.60 Furthermore, SIRT1 also 
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!promotes mobilization of free fatty acids from WAT by repressing PPARγ 
activity, an effect lost in SIRT1-/- mice.60  
The liver is the main organ for the synthesis of cholesterol, free fatty 
acids and bile acids. Liver-specific deletion of SIRT1 results in an increase in 
hepatic steatosis and inflammation, while liver-specific overexpression of 
SIRT1 results in protection against high-fat diet-induced hepatic steatosis. In 
fasted mice, SIRT1 is induced in the liver where it deacetylates PGC1α 
resulting in the induction of gluconeogenic and fatty acid oxidation genes.61 
The expression of SIRT1 and PGC1α was shown to correlate with the 
intracellular concentrations of the metabolite - pyruvate, a metabolite 
associated with fasting.56 These findings suggest that PGC1α undergoes 
cycles of acetylation and deacetylation during fed and fasted states, which 
correlate with SIRT1 expression. Loss of SIRT1 impairs the activity of hepatic 
PPARα due to lack of PGC1α deacetylation resulting in a decrease in fatty 
acid oxidation, thereby increasing steato-hepatitis in mice fed a high-fat 
diet.62.  
Currently, SIRT1 is recognized as a modulator of hepatic cholesterol 
levels by deacetylating LXR and PGC1α.57, 61 Deacetylation of LXR leads to 
an increase in cholesterol efflux resulting from an increase in ABCA1 
expression (a membrane transporter involved in HDL synthesis).57 Increase in 
LXR activity by SIRT1 promotes reverse cholesterol transport and increases 
the synthesis of bile acids. In line with this, livers of SIRT1-/- mice have 
reduced mRNA levels of LXR target genes, including Cyp7A1, SREBP1c and 
fatty acid synthase.63 Since excess cholesterol can be cleared from cells 
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!through activation of SIRT1, many researchers have studied the role of SIRT1 
in cardiovascular disease.54-57 
Figure 5. SIRT1 modulates multiple targets in the liver. An increase in 
NAD+ levels activates SIRT1 causing deacetylation of LXR, PGC1α, 
SREBP1c and FOXO1 which leads to an increase in reverse cholesterol 
transport, gluconeogenesis and insulin sensitivity with a decrease in fatty acid 
synthesis. 
3.8 SIRT1 and cardiovascular disease 
Cardiovascular disease and aging pose a major risk to mortality in the 
developing world. Since the risk of coronary artery disease and congestive 
heart failure increase with age, SIRT1 has been extensively studied in 
cardiovascular disease. In aged mouse arteries, SIRT1 expression is reduced 
thus increasing the risk of endothelial damage.64 SIRT1 has an extensive role 
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!in protection against inflammation and cell survival by acting as a potent anti-
senescence and anti-inflammatory protein in different tissues through various 
mechanisms. In the endothelium, SIRT1 expression is very abundant and 
functions as a novel modulator of angiogenesis.65 SIRT1 does this by 
deacetylating the angiogenesis-regulator FOXO1, resulting in endothelial 
remodelling and maintenance through an increase in FOXO1 target gene 
expression. 
Endothelial dysfunction is involved in the formation of early lesions in 
atherosclerosis and is well established as a cardiovascular risk. Thus 
understanding the role of SIRT1 in endothelial dysfunction is key to discerning 
the benefits of SIRT1 activation in atherosclerosis. SIRT1 was found to 
negatively regulate p66 expression, a key player in endothelial dysfunction, 
through epigenetic modification.66 Downregulation of p66 in the endothelium 
protects against hyperglycaemia-induced endothelial dysfunction. Another 
hallmark of endothelial dysfunction is the reduction of eNOS activity and 
expression.67 The activity and expression of eNOS directly correlates with the 
activity and/or expression of SIRT1. SIRT1 deacetylates eNOS in the 
endothelium suggesting that SIRT1 impedes endothelial dysfunction by 
increasing the activity of eNOS.68 In support of this, endothelium-specific 
overexpression of SIRT1 protects against atherogenesis in mice fed a high-fat 
diet by promoting endothelium-dependent vasodilation through eNOS. SIRT1 
also inhibits oxLDL-induced endothelial cell apoptosis in vitro.69 Furthermore, 
SIRT1 can downregulate inflammation by deacetylating and inhibiting p65 
activity.70 Deacetylation of p65 lead to suppression of chemokine secretion 
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!and downregulation of scavenger receptors in macrophages, thus reducing 
endothelial activation and foam cell formation.71, 72  
Cyclin-dependent kinase 5 (CDK5) is a kinase that blocks the activity of 
SIRT1 by phosphorylating SIRT1 at serine 47 position. In favour of an 
atheroprotective function of SIRT1, prevention of CDK5-mediated 
hyperphosphorylation of SIRT1 by Roscovitine, a CDK5 inhibitor, prevents the 
development of atherosclerosis in ApoE-/- mice.73 Similar to macrophages, 
SIRT1 plays a protective role in vascular smooth muscle cells as well. 
Vascular smooth muscle cell-specific overexpression of SIRT1 increases DNA 
repair by deacetylating and activating Nijmegen Breakage Syndrome-1 
protein. In support of this, deletion of SIRT1 in vascular smooth muscle cells 
of ApoE-/- mice showed an increase in oxLDL-induced DNA damage leading 
to atherogenesis and plaque formation.74 
The role of SIRT1 has been investigated in patients suffering from 
cardiovascular disease as well. Human atherosclerotic plaques have reduced 
mRNA and protein expression of SIRT1 compared to normal vessels of 
patients with coronary artery disease.74 SIRT1 expression in monocytes is 
reduced in patients with stable coronary artery disease and acute coronary 
syndrome.75 Moreover, patients with mutations of SIRT1 gene (haplotype 2 
carriers) have been shown to have a reduced risk of cardiovascular disease,76 
Thus, these findings suggest that increasing SIRT1 expression and activity in 
patients suffering from atherosclerosis may have a therapeutic potential in 
humans. 
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!3.9 SIRT1 activators in animal studies 
On the rationale that caloric restriction activates SIRT1 and has positive 
effects on health, the discovery of SIRT1 activators has provided a novel 
approach to mimic the benefits of caloric restriction in patients. Resveratrol 
was the first synthetic sirtuin activating compound (STAC), and still the most 
potent, natural-occurring compound found to activate SIRT1 in vitro. By 
activating SIRT1, resveratrol reduces ischaemic injuries in various tissues 
including the brain, heart and kidney, and improves vascular function.77, 78 
These protective effects were shown to involve eNOS activation and a 
reduction in cytokine production. Resveratrol reduces LPS-induced 
inflammatory responses of macrophages and peripheral blood monocytes in 
vitro.79 Administration of resveratrol to patients at risk of CVD led to reduced 
levels of oxLDL and an improved lipid profile.80 Furthermore, resveratrol 
mimicked the beneficial effects of SIRT1 in vivo, consistent with animal 
models overexpressing SIRT1. 
Later on, however, resveratrol was shown to have SIRT1-independent 
effects, which were shown to involve activation of AMPK.81 The discovery of 
synthetic STACs, distinct from resveratrol brought new hope for SIRT1 
activation as a therapeutic target in a clinical setting. The STAC, SRT1720, 
was shown to reduce energy expenditure and lower plasma total cholesterol 
and LDL-cholesterol levels in obese mice, thus highlighting a potential role for 
SRT1720 as an LDL-cholesterol lowering agent.82 Similarly, SRT1720 was 
shown to reduce the incidence of myocardial infarction.83  
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!3.10 SIRT1 activators and their specificity 
Although the effects of STACs are well documented, the mechanism by which 
STACs activate SIRT1 is still controversial. Originally STACs were thought to 
activate SIRT1 by lowering its Michaelis constants (Km) for both SIRT1 protein 
substrates and NAD+, thus allowing for an increase in deacetylase activity. 
Since then, there has been a lot of speculation that the published SIRT1 
activators do not directly bind to and activate SIRT1 but act via an indirect 
mechanism through other proteins. 
The first lead molecule to activate SIRT1 - resveratrol, was indeed 
shown to activate SIRT1 indirectly through AMPK activation.81 The study 
showed that the AMPK agonist 5-aminoimidazole-4-carboxamide 
ribonucleotide (AICAR) increased NAD+ levels and caused an increase in 
PGC1α deacetylation in a SIRT1-dependent manner. Thus, the validity of 
resveratrol as a genuine SIRT1 activator was questioned. Furthermore, the 
initial assay to determine natural activators was a fluorometric assay called 
‘Fluor de Lys’, in which acetylated peptide substrates of SIRT1 were non-
covalently conjugated to aminomethylcoumarin (AMC), while synthetic 
activators were assessed by fluorescence polarization assay with 
carboxytetramethylrhodamine (TAMRA) –conjugated substrates and verified 
by mass spectrometry. Due to the large size of the fluorophores conjugated to 
SIRT1 substrates, this strategy of assessing STACs was highly criticized. 
Using NMR, surface plasmon resonance, and isothermal calorimetry 
techniques, Pacholec et al. proved that the STACs at that time - SRT1720, 
SRT2183 and SRT1460 and resveratrol, directly interact with the fluorophore-
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!containing peptide substrates of the SIRT1 activity assay.84 Thus, they 
showed that the SIRT1 activity of these synthetic activators was an in vitro 
artefact. Such findings questioned the validity of this SIRT1 activity assay to 
detect novel SIRT1 activators and assess the SIRT1 activation potency of 
these drugs. 
However, recent studies have vindicated the SIRT1 activity assay by 
showing that activation of SIRT1 by STACs is also dependent on the 
structural features of the peptide substrate.85 Furthermore, another study 
showed that the fluorophore tags conjugated to the substrates used in the 
assay mimic the hydrophobic amino acids of natural substrates at the same 
position as the fluorophore. Thus this study suggested that synthetic SIRT1 
activators discovered by the Fluor de Lys, or TAMRA assay tend to selectively 
deacetylate SIRT1 targets that have large hydrophobic residues (like Trp, Tyr 
or Phe) at the same position (eg. PGC1α-K778 and Foxo3a-K290).86 Thus 
current SIRT1 activators indeed tend to activate SIRT1 by allosteric binding, 
however, they cause the deacetylation of only selected substrates. 
Accordingly, SIRT1 activators indeed activate SIRT1. SRT3025 is a new 
SIRT1 activator, discovered by the same process and is considered to have a 
similar mechanism of SIRT1 activation. SRT3025 causes an increase in 
activation of wild-type SIRT1 but fails to activate a SIRT1 mutant resistant to 
activation (E230K in which Glu230 is mutated to Lys). The beneficial effects of 
SIRT1 activators like SRT3025 have yet to be assessed in atherosclerosis. 
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!4. Hypothesis, aims and design
4.1 Hypothesis 
Based on our previous findings and recent observations described above, we 
hypothesize that, 
Sirt1 activation by SRT3025 protects ApoE-/- mice against 
atherosclerosis by reducing inflammation and lowering plasma low-
density lipoprotein cholesterol. 
Figure 6. Overview of project hypothesis. SIRT1 activation by an activator 
reduces inflammation by decreasing cytokine and adhesion molecules and 
improves lipid dysfunction by increasing cholesterol efflux, insulin sensitivity 
and inhibiting free fatty acid synthesis. The inhibition of inflammation and 
improvement of plasma lipid profile, both contribute to a decrease in 
atherosclerosis. 
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!4.2 Specific aims 
Based on the above hypothesis, we formulated the following specific aims, 
Aim 1: To assess the effects of SIRT1 activator SRT3025 on atherosclerosis 
in ApoE-/- mice fed a high-cholesterol diet. 
Aim 2: To assess the effects of SIRT1 activator SRT3025 on inflammation in 
ApoE-/- mice fed a high-cholesterol diet. 
Aim 3: To assess the effects of SIRT1 activator SRT3025 on plasma 
cholesterol levels in ApoE-/- mice fed a high-cholesterol diet. 
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4.3 Experimental design 
8-week old ApoE-/- mice were fed a high-cholesterol diet (with 1.25% 
cholesterol) and supplemented with and without SRT3025 (3.18g/kg diet) for 
12 weeks. 
 
  
 
Figure 7. Overview of the experimental design for experimental 
atherosclerosis. 8-week old ApoE-/- mice on a normal chow were placed on 
a 1.25% high-cholesterol diet supplemented with and without SIRT1 activator, 
SRT3025 (3.18g/kg diet) for 12 weeks. After 12 weeks the mice were 
sacrificed and assessed for atherosclerosis. 
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Aims Thedeacetylase sirtuin1 (Sirt1) exertsbeneficial effectson lipidmetabolism, but its roles inplasmaLDL-cholesterol regu-
lation and atherosclerosis are controversial. Thus, we applied the pharmacological Sirt1 activator SRT3025 in a mouse
model of atherosclerosis and in hepatocyte culture.
Methods
and results
Apolipoprotein E-deficient (Apoe2/2) mice were fed a high-cholesterol diet (1.25% w/w) supplemented with SRT3025
(3.18 g kg21 diet) for 12 weeks. In vitro, the drug activated wild-type Sirt1 protein, but not the activation-resistant
Sirt1 mutant; in vivo, it increased deacetylation of hepatic p65 and skeletal muscle Foxo1. SRT3025 treatment decreased
plasma levels of LDL-cholesterol and total cholesterol and reduced atherosclerosis. Drug treatment did not change
mRNA expression of hepatic LDL receptor (Ldlr) and proprotein convertase subtilisin/kexin type 9 (Pcsk9), but
increased their protein expression indicating post-translational effects. Consistent with hepatocyte Ldlr and Pcsk9 accu-
mulation, we found reduced plasma levels of Pcsk9 after pharmacological Sirt1 activation. In vitro administration of
SRT3025 to cultured AML12 hepatocytes attenuated Pcsk9 secretion and its binding to Ldlr, thereby reducing Pcsk9-
mediated Ldlr degradation and increasing Ldlr expression and LDL uptake. Co-administration of exogenous Pcsk9
with SRT3025 blunted these effects. Sirt1 activation with SRT3025 in Ldlr2/2 mice reduced neither plasma Pcsk9, nor
LDL-cholesterol levels, nor atherosclerosis.
Conclusion We identify reduction in Pcsk9 secretion as a novel effect of Sirt1 activity and uncover Ldlr as a prerequisite for Sirt1-
mediated atheroprotection in mice. Pharmacological activation of Sirt1 appears promising to be tested in patients for
its effects on plasma Pcsk9, LDL-cholesterol, and atherosclerosis.
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Translational perspective
The deacetylase Sirt1 exerts beneficial effects on metabolic and inflammatory diseases. However, its effects on lipid metabolism and athero-
sclerosis remain controversial. Lowering plasma Pcsk9 emerges as a promising therapeutic strategy to lower plasma LDL-cholesterol. Unlike
current antibody-based strategies that act on extracellular Pcsk9 activity, we found an alternative route to decrease Pcsk9-mediated Ldlr deg-
radation: pharmacological Sirt1 activation reducedhepatic Pcsk9 secretion, increasedLdlr expression, anddecreasedplasmaLDL-cholesterol
and atherosclerosis in mice. Thus, Sirt1 activation appears as a promising approach to be tested for atheroprotection in patients.
Introduction
Atherosclerosis results fromacomplex interplaybetween innate and
adaptive immunity involving modified LDL-cholesterol, activated
endothelial cells, and monocyte-derived macrophages within the ar-
terialwall. Sirt1 is amemberof the sirtuin familyofNAD+-dependent
deacetylases.1 Studies on the role of Sirt1 in atherosclerosis have
reported controversial effects.
Sirt1 has been shown to be atheroprotective in apolipoprotein
E-deficient (Apoe2/2) mice2–4 whereas genetic overexpression of
Sirt1 in LDL-receptor-deficient (Ldlr2/2) mice enhanced athero-
sclerosis.5 The role of Sirt1 in regulation of plasma LDL-cholesterol
concentration, the key trigger of atherogenesis,6 remains in-
completely understood. Hepatic deletion of Sirt1 in C57BL/6 mice
fed a high-cholesterol diet induced mild hypercholesterolemia.7
Conversely, administration of a Sirt1 activating drug to elderly vol-
unteers and cigarette smokers decreased plasma levels of total and
LDL-cholesterol.8,9 These studies suggest that Sirt1 regulates
plasma LDL-cholesterol.
Hepatic Ldlr clears LDL-cholesterol from the blood stream.10,11
Transcription of Ldlr is controlled by the sterol-responsive
element binding protein 2 (Srebp2),12 while its turnover depends
on proprotein convertase subtilisin/kexin type 9 (Pcsk9), a serine
protease.13 SecretedPcsk9 targets hepaticLdlr for lysosomal degrad-
ation and thus prevents recycling of internalized Ldlr to the cell
surface.14
We hypothesized that hepatic Ldlr mediates the effects of Sirt1
on plasma LDL-cholesterol levels and thus provides atheroprotec-
tion. To test this hypothesis, we fed Apoe2/2 or Ldlr2/2 mice a
high-cholesterol diet supplemented with the novel Sirt1 acti-
vator SRT3025 or placebo, and investigated atherogenesis and lipid
metabolism.
Methods
Detailed information is available in Supplementary material online.
Animals
Male Apoe2/2 or Ldlr2/2 mice on a pure C57BL/6J background were
housed with a 12 h light–dark cycle and fed a high-cholesterol diet con-
taining 1.25% cholesterol (D12108; Research Diets) supplemented with
or without (SRT3025, 3.18 g kg21 diet, provided by Sirtris, Cambridge,
MA,USA) for 12weeks starting at the ageof 8weeks.After this treatment
period, mice were sacrificed (after overnight fasting), EDTA blood was
taken and tissues were harvested. All experiments and animal care pro-
cedures were approved by the local veterinary authorities and carried
out in accordance with our institutional guidelines.
Cell culture
AML12 mouse hepatoma cells were cultured in a 1:1 (v/v) mixture of
DMEM and Ham’s F12 medium supplemented with insulin (5 mg ml21),
transferrin (5 mg ml21), selenium (5 ng ml21), dexamethasone
(40 ng ml21), and 10% FBS (v/v). Where indicated, AML12 cells were
exposed to 10 mM SRT3025 in 1% DMSO (v/v).
Statistics
All data are presented as means+ SD. Data distribution was assessed
using the Kolmogorov–Smirnov test. Normally distributed data were
compared by an unpaired two-tailed Student’s t-test; for non-parametric
data theMann–Whitney testwasused.Threeormoregroupswerecom-
pared using a Kruskal–Wallis test followed by a Dunn’s post-hoc com-
parison (non-parametric data). At least three independent experiments
in triplicates were performed. Significance was accepted at P, 0.05.
Analyses were done using Graphpad Prism (version 5.0d, 2010).
Results
SRT3025 reduces plasma cholesterol,
inflammation, and atherosclerosis
in Apoe2/2mice
Histomorphometry of thoraco-abdominal aortae en face and cross-
sections of aortic roots revealed a significant reduction in plaque size
in SRT3025-treated Apoe2/2 mice compared with placebo-treated
controls (Figure 1A and B). Moreover, a marked reduction of
Cd68-positive macrophages within the plaque and Vcam-1 expres-
sion in aortic roots was observed (Figure 1C and D). Interestingly,
plasma levels of total-, LDL- and VLDL-cholesterolwere significantly
lower after SRT3025 treatment compared with placebo (Figure 1E
and F ). Triglycerides and HDL-cholesterol remained unchanged
(Supplementarymaterial online, Figure S1A). In addition,weobserved
reduced plasma levels ofMcp-1 and Il-6 (Figure 1G) and lower hepatic
mRNA expression of these cytokines (Figure 3A).
These findings indicate that SRT3025 administration to Apoe2/2
mice provides atheroprotection and reduces plasma LDL-cholesterol
and inflammation.
SRT3025 mimics Sirt1 activity in vitro
and in Apoe2/2mice
SRT3025 concentration-dependently activated wild-type Sirt1, but
failed to activate the activation-resistant Sirt1 mutant E230K in vitro
(Figure 2A). Increased deacetylation of known Sirt1 targets upon
SRT3025 treatment, hepatic p65 and forkhead transcription factor
family O1 (Foxo1) in skeletal muscle (Figure 2B and C ) indicate suc-
cessful Sirt1 activation in vivo. SRT3025 prevented an increase in
weight gain and epididymal white adipose tissue without affecting
food intake, thereby mimicking a caloric restriction phenotype
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Figure 1 SRT3025 confers atheroprotection, reduces plasma cholesterol and systemic inflammation in Apoe2/2 mice. Eight-week-old Apoe2/2
mice were fed a high-cholesterol diet (1.25% w/w) supplemented with the Sirt1 activator SRT3025 (n ¼ 9) or placebo (n ¼ 9) for 12 weeks. Rep-
resentativemicrographs (left) andquantifications (right) of thoraco-abdominal aortae en face (A) andof aortic root cross sections (B–D) stainedwith
OROor immunohistochemically formacrophages (Cd68) orVcam-1; (E) cholesterol distribution in the different lipoprotein subfractions separated
by gel filtration chromatography; (F ) Plasma total cholesterol, LDL-, andVLDL-cholesterol concentrations; (G) Plasma levels ofMcp-1 and Il-6. Scale
bars inphotomicrographs: 1 mm(A) and500 mm(B–D).HCD,high-cholesterol diet;AU, arbitraryunits; LDL, low-density lipoprotein;ORO,oil-red
O; VLDL, very low-density lipoprotein; Vcam-1, vascular cell adhesion molecule 1; Mcp-1, monocyte chemoattractant protein 1; Il-6, interleukin 6.
Figure 2 SRT3025 mimics Sirt1 activity in vitro and in Apoe2/2 mice. (A) Concentration-response curve of SRT3025 on the activity of wild-type
Sirt1 and activation-resistant mutant E230K in vitro. (B, C )Western blots for acetylation status of Sirt1 target proteins (B) p65 and (C) Foxo1 immu-
noprecipitated from nuclear extracts of liver and skeletal muscle, respectively, from Apoe2/2 mice fed a high-cholesterol diet (1.25% w/w) supple-
mented with the Sirt1 activator SRT3025 or placebo for 12 weeks. HCD, high-cholesterol diet; Ac-Ly, anti-acetyl-lysine antibody.
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(Supplementary material online, Figure S1B–D). Pharmacokinetic
analysis of the drug in Apoe2/2 mice showed that the drug indeed
reached target tissues (Supplementary material online, Table S1).
Plasma protein levels of glutamic oxaloacetic transaminase, glutamic
pyruvic transaminase, and alkaline phosphatase were not different
between drug- and placebo-treated mice (Supplementary material
online, Figure S1E).
SRT3025 increases hepatic Ldlr expression
and Pcsk9 accumulation in Apoe2/2mice
Pharmacological Sirt1 activation increased liver expression of Abca1,
but did not affect Abcg5, Abcg8, Ldlr, Pcsk9, Ppara, Pparg, Srebp1, and
Srebp2 (Figure 3A). Despite no changes in Ldlr and Pcsk9 mRNA
expression, both were markedly increased at the protein level
(Figure 3A and B). This intracellular accumulation of Pcsk9 protein
with no change inmRNA suggests a disturbed transport and/or secre-
tion of the protein. In agreement with this, we found reduced plasma
Pcsk9 protein levels following pharmacological Sirt1 activation in
Apoe2/2 mice compared with placebo-treated controls (Figure 3C).
SRT3025 increases Ldlr expression and
Pcsk9accumulation inAML12hepatocytes
To delineate the mechanisms by which SRT3025 affects Ldlr protein
expression, we performed in vitro experiments administering
SRT3025 to mouse hepatoma AML12 cells. We observed a
concentration- and time-dependent increase in Ldlr and Pcsk9
protein expression upon SRT3025 administration in cell lysates
(Figure 4A and B). As observed in vivo, mRNA levels of Ldlr and
Pcsk9 were not altered by SRT3025 (Figure 4C), indicating that post-
translational effects cause the changes in protein expression.
Incubation of AML12 cells with 10 mM SRT3025 was associated
with a time-dependent decrease in Pcsk9 secretion into the super-
natant (Figure 4D). Moreover, co-immunoprecipitation of endogen-
ous Pcsk9 and Ldlr after 24 h incubation with 10 mM SRT3025
revealed that Pcsk9binding to Ldlrwas impaired after SRT3025 treat-
ment compared with vehicle control (Figure 4E). Thus, the question
arises whether the increase in hepatic Ldlr protein expression
upon Sirt1 activation is related to limited extracellular availability of
Pcsk9 and/or a defective degradation of internalized Ldlr.
SRT3025 impairs Pcsk9-dependent
degradation of Ldlr in AML12 hepatocytes
Toaddress theabovequestion,westimulatedAML12cellswith10 mM
SRT3025 for 24 h and compensated for the decrease in extracellular
Pcsk9 by adding exogenous active Pcsk9 protein. Co-administration
of Pcsk9 [3 ng ml21, based upon concentrations measured in the
supernatants of untreated AML12 (Figure 4D)] and SRT3025 to
AML12 hepatocytes attenuated the drug-dependent increase in
Ldlr protein expression (Figure 5A). These data indicate that the in-
ternalization and degradation process of Ldlr is not defective and
that limited extracellular availability of Pcsk9 contributes to the in-
crease in Ldlr protein expression.
Fluorescence analysis revealed an increase in labelled LDL uptake
upon 10 mM SRT3025 treatment compared with vehicle controls
(Figure 5B), suggesting a functional relevance of the SRT3025-
dependent increase in Ldlr expression. Moreover, co-administration
of exogenous active Pcsk9 also attenuated the drug-induced increase
Figure3 SRT3025 increases hepatic Ldlr protein expressionwhile decreasingplasmaPcsk9 inApoe2/2mice. Eightweek-oldApoe2/2micewere
fed a high-cholesterol diet (1.25%w/w) supplementedwith the Sirt1 activator SRT3025 (n ¼ 9) or placebo (n ¼ 9) for 12weeks. (A) RelativemRNA
expression levels of hepatic genes involved in cholesterol regulation. (B)Western blots of liver lysates for Ldlr, Pcsk9, andb-actin. (C) Plasma levels of
Pcsk9. HCD, high-cholesterol diet; Pcsk9, proprotein convertase subtilisin/kexin type 9.
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Figure 4 SRT3025 increases Ldlr expression in AML12 hepatocytes and decreases Pcsk9 in the supernatant. Western blots of Ldlr, Pcsk9, and
b-actin in culturedAML12 cells (A) treatedwith SRT3025 at indicated concentrations for 24 h and (B) incubatedwith 10 mMSRT3025 for the times
indicated. (C) Relative mRNA expression levels of Ldlr and Pcsk9 in AML12 cells after incubation with 10 mM SRT3025 for 24 h. (D) Pcsk9 protein
levels in the supernatant of AML12 cells incubated with 10 mM SRT3025 for the times indicated. (E) Pcsk9 immunoprecipiated from AML12 cells
incubated with vehicle (Veh, DMSO) or 10 mM SRT3025, and blotted for Ldlr and Pcsk9. Pcsk9, proprotein convertase subtilisin/kexin type 9.
Figure5 Exogenous Pcsk9 prevents SRT3025-induced increase in Ldlr expression and activity in AML12 hepatocytes. (A)Western blot and cor-
respondingquantifications ofAML12 cells treatedwith vehicle (Veh,DMSO)or 10 mMSRT3025 and incubatedwithorwithout Pcsk9 active protein
(3 ng ml21) for 1 h. (B) BODIPY-labelled LDL uptake in AML12 cells incubated for 24 hwith 10 mMSRT3025 or Veh and incubatedwith orwithout
Pcsk9 active protein (3 ng ml21) for 1 h. Fluorescence intensity and western blot quantifications are given as percentage of Veh control. BODIPY,
4,4-difluoro-3a,4a-diaza-s-indacene; AU, arbitrary units; Pcsk9, proprotein convertase subtilisin/kexin type 9.
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in LDL uptake (Figure 5B), consistent with the observed attenuation
of Ldlr protein expression (Figure 5A).
These data indicate that SRT3025decreases hepatic Pcsk9 release,
impairs Pcsk9 binding to hepatic Ldlr, and thereby prevents hepatic
Ldlr degradation. These events result in increased hepatic Ldlr
expression and enhanced LDL-cholesterol plasma clearance.
Increased Ldlr protein expression in
AML12 hepatocytes is mediated by Sirt1
To assess whether this increase in Ldlr protein expression is
Sirt1-dependent, Sirt1 knockdown in AML12 cells was performed
in the presence of 10 mM SRT3025. In contrast to control scramble
siRNA-treated cells, cells transfected with Sirt1 siRNA did not show
an increase in Ldlr expression upon SRT3025 addition (Figure 6A).
Conversely, genetic overexpression of Sirt1 increased Ldlr protein
expression in AML12 cells compared with control transfec-
tion (Figure 6B). Thus, Sirt1 is required for SRT3025-induced in-
crease in Ldlr protein expression.
Genetic deletion of Ldlr abolishes
atheroprotectiveeffectsofSRT3025 invivo
Given the critical role of hepatic Ldlr in the clearance of plasma
cholesterol and our observation of increased hepatic Ldlr expres-
sion in SRT3025-treated Apoe2/2 mice, we investigated whether
Ldlr accounts for the atheroprotective effects of SRT3025. For that
purpose, similar experiments were performed in Ldlr2/2 mice.
Plaque analyses of thoraco-abdominal aortae en face and cross-
sections of aortic roots revealed no difference in the extent of ath-
erosclerosis between drug- and placebo-treated mice (Figure 7A
and B). Furthermore, the number of plaque-resident macrophages
(Cd68) and Vcam-1 expression in aortic roots did not differ
between the groups (Figure 7C and D).
Plasma lipids showed an increase in total and VLDL-cholesterol
in SRT3025-treated Ldlr2/2 mice compared with placebo-treated
controls (Figure 7E and F ), whereas plasma LDL-cholesterol,
HDL-cholesterol, and triglycerides were unaffected by drug treat-
ment (Figure 7F and Supplementary material online, Figure S2A).
As in Apoe2/2 mice, SRT3025 prevented an increase in weight gain
and epididymal white adipose tissue without affecting food intake
(Supplementary material online, Figure S2B–D), and lowered plasma
levels of pro-inflammatory cytokinesMcp-1 and Il-6 (Figure 7G). Com-
paredwithApoe2/2mice, baseline plasma Pcsk9 levels in Ldlr2/2mice
were about 20-fold higher (Figure 7G). SRT3025 induced aminimal but
significant increase in plasma Pcsk9 levels in Ldlr2/2 mice (Figure 7G).
Pharmacological Sirt1 activation decreased the expression of Ppara,
but did not affect Abcg5, Abcg8, Abca1, Pcsk9, Pparg, Srebp1, Srebp2,
Mcp-1 and Il-6 (Supplementary material online, Figure S2E).
Discussion
We demonstrate that pharmacological Sirt1 activation using
SRT3025 attenuated Pcsk9 secretion from murine hepatocytes in
vitro and lowered plasma levels of Pcsk9 in atherosclerosis-prone
Apoe2/2 mice in vivo. As a consequence, hepatocyte Ldlr expression
and activity were increased leading to a decrease in plasma
LDL-cholesterol and atherosclerotic plaques in Apoe2/2 mice.
None of these variables were changed in Ldlr2/2 mice despite a
similar decrease in systemic inflammation. Thus, our findings identify
reduced Pcsk9 secretion and increased Ldlr expression as novel
downstream effects of Sirt1 activity and highlight the potential
of pharmacological Sirt1 activation as a novel anti-atherosclerotic
strategy.
SRT3025 was found to activate wild-type Sirt1 protein but failed
to activate the E230K mutant, an activation-resistant Sirt1 protein
Figure 6 Sirt1 knockdown reduces and Sirt1 overexpression enhances SRT3025-induced increase in Ldlr expression in AML12 hepatocytes.
(A) Western blots of Ldlr, Sirt1, and b-actin with corresponding quantifications of AML12 cell lysates following transfection with Sirt1 siRNA or
scrambled siRNA for 24 h and incubated with 10 mM SRT3025 or vehicle (Veh, DMSO) for additional 24 h. (B) Western blots of Ldlr, Sirt1, and
b-actinwith corresponding quantifications of AML12 cell lysates following Sirt1 overexpression plasmid or scramble control for 24 h and incubated
with 10 mMSRT3025 or Veh for additional 24 h.Western blot quantifications are given as a percentage of Veh control. Scr, scramble plasmid; Sirt1
OE, Sirt1 overexpression plasmid.
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(due to a mutation at position 230). Thus, similar to previously
described Sirt1 activators,15 SRT3025 acts by allosteric binding to
Sirt1 at the lysine site 230, which is located at its catalytic core. Ana-
lyses of the acetylation status of the Sirt1 target Foxo1 in skeletal
muscle and p65 in the liver show that SRT3025 increases deacetyla-
tion of Sirt1 target proteins in vivo. Furthermore, the increase in
Ldlr protein expression in AML12 cells in vitro in response to stimu-
lation with the Sirt1 activator was time- and concentration- depend-
ent and could be attenuated by knockdown of Sirt1, while genetic
Sirt1 overexpression mimicked the effects of SRT3025. These data
indicate that the SRT3025-associated changes in Ldlr expression
are Sirt1-dependent.
Endothelial-specific overexpression of Sirt1 in Apoe2/2 mice was
reported to protect against atherosclerosis by increasing endothelial
eNOS activity.2 Furthermore, using partial Sirt1 deletion in Apoe2/2
mice, we have shown that Sirt1-induced inhibition of NFkB impairs
endothelial expression of the macrophage scavenger receptor
Lox-1, and thus attenuates foamcell formation.3Although these find-
ings address beneficial effects of Sirt1 in a particular setting of athero-
sclerosis, they provide limited insight into the effects of Sirt1 on
cholesterol metabolism. Interestingly, hepatic deletion of Sirt1 in
C57BL/6 mice fed a high-cholesterol diet was associated with a
mild increase in plasma LDL-cholesterol,7 suggesting that hepatic
Sirt1 regulates plasma LDL-cholesterol. In line with these findings,
Apoe2/2 mice treated with SRT3025 showed an increase in hepatic
Ldlr expression accompanied by a significant reduction in plasma
LDL-cholesterol levels. Moreover, the extent of aortic atheroscler-
osis and the plasma levels of LDL-cholesterol were unchanged in
Ldlr2/2 mice, highlighting the importance of Ldlr for the athero-
protective and lipid-lowering effects of Sirt1. Of note, we observed
a similar reduction in plasma levels of pro-inflammatory cytokines
in bothApoe2/2 and Ldlr2/2mice,whereas a reduction in plaque for-
mation was only observed in Apoe2/2 mice with endogenous Ldlr.
Therefore, our data suggest that not the reduction in inflammation,
which still occurs in the absence of Ldlr, but the decrease in plasma
LDL-cholesterol accounted for reducing atherosclerosis in
Apoe2/2 mice treated with SRT3025. Moreover, since we observed
a reduction in weight gain in both Apoe2/2 and Ldlr2/2 mice despite
unaltered food intake, the atherosclerotic phenotype is also inde-
pendent of changes in bodyweight. Taken together, we demonstrate
that the increased expression of hepatic Ldlr is essential for the
cholesterol-lowering effects of SRT3025.
In line with our findings, clinical studies with another Sirt1 ac-
tivator have shown a reduction in plasma total cholesterol and
Figure 7 Genetic deletion of Ldlr abolishes anti-atherosclerotic effects of SRT3025 in vivo. Eight-week-old Ldlr2/2 mice were fed a high-
cholesterol diet (1.25% w/w) supplemented with the Sirt1 activator SRT3025 (n ¼ 9) or placebo (n ¼ 9) for 12 weeks and fasted for 12 h
before blood was drawn and aortae were explanted. Representative micrographs (left) and quantifications (right) of thoraco-abdominal aortae
en face (A) and of aortic root cross sections (B–D) stained with oil-red O (ORO) or immunohistochemically for macrophages (CD68) or
Vcam-1; (E) cholesterol distribution in thedifferent lipoprotein subfractions separated by gel filtration chromatography; (F) plasma total cholesterol,
LDL-, and VLDL-cholesterol concentrations; (G) plasma levels of Mcp-1, Il-6, and Pcsk9. Scale bars in photomicrographs ¼ 1 mm (A) and 500 mm
(B–D). HCD, high-cholesterol diet; AU, arbitrary units; LDL, low-density lipoprotein; ORO, oil-redO; VLDL, very low-density lipoprotein; Vcam-1,
vascular cell adhesionmolecule 1;Mcp-1,monocyte chemoattractant protein 1; Il-6, interleukin 6; Pcsk9, proprotein convertase subtilisin/kexin type 9.
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LDL-cholesterol.8,9 The presently observed reduction in VLDL-
cholesterol in mice has yet to be assessed in patients. Furthermore,
constitutive Sirt1 overexpression in Ldlr2/2 mice was associated
with increased atherosclerosis.5 Pharmacological Sirt1 activation
using anoral Sirt1 activator and constitutive genetic Sirt1overexpres-
sion are likely to differ in efficiency and may exert differential effects
on genes involved in lipid metabolism. Moreover, a difference in
NAD+ availability between both models may affect Sirt1 activity.16
It remains to be seen whether constitutive Sirt1 overexpression is
associated with enhanced hepatic expression of Ldlr in Apoe2/2
mice.
Ldlr plays a critical role in the regulationof plasmaLDL-cholesterol
levels,10,11 a key determinant of atherogenesis.17 Mice overexpres-
sing hepatic Ldlr have reduced plasma LDL-cholesterol levels and
are protected from plaque formation, whereas Ldlr-deficient mice
exhibit increased levels of plasma LDL- and VLDL-cholesterol and
are prone to atherosclerosis when exposed to a high-cholesterol
diet.4,18 We show that Ldlr protein expression is increased despite
no change in Ldlr mRNA, indicating a post-translational mechanism.
Indeed, degradation of Ldlr protein in liver cells is regulated via
secreted Pcsk9, a serine protease that predominantly originates
from the liver.14,19 By binding to the EGF-A domain of Ldlr, Pcsk9
targets this receptor for lysosomal degradation rather than for recyc-
ling to the cell surface.20,21 Ldlr was reported to be themain route of
Pcsk9 clearance.22 In agreement with this, we found markedly
increased plasma Pcsk9 levels in mice lacking Ldlr.
In our study, both SRT3025 treatment and Sirt1 overexpression
increased Ldlr protein expression in AML12 cells, while reducing
the concentration of Pcsk9 in the supernatant and lowering the
amount of Pcsk9 bound to Ldlr, despite no change in Pcsk9 transcrip-
tion. Notably, exogenous addition of active Pcsk9 to AML12 cells
treated with SRT3025 decreased Ldlr protein expression and
reduced LDL uptake by the cells. These data indicate that Ldlr intern-
alization and degradation are not disrupted by SRT3025 treatment
and can be re-induced upon exogenous addition of Pcsk9.Moreover,
thesedatademonstrate that it is the limitedextracellular availabilityof
Pcsk9 that contributes to the increase in Ldlr protein expression, sug-
gesting that plasma Pcsk9 levels are an important determinant of
hepatic Ldlr protein surface expression in our model. The mechan-
isms bywhich Sirt1 affects Pcsk9 secretion remain to be investigated.
Yet, the specific investigation of Pcsk9-dependent alterations on ath-
erosclerosis may be hampered by reciprocal changes in Ldlr.22
Conclusions and perspectives
Our studydescribes a novelmechanism that causally links Sirt1 to the
metabolism of LDL-cholesterol in vitro and in vivo. We demonstrate
that Sirt1 activation increases hepatic Ldlr protein expression
through a reduction in Pcsk9-mediated Ldlr degradation leading to
decreased plaque formation.
Of note, statin therapy not only increases hepatic Ldlr, but also
plasma Pcsk9 activity, thus limiting its effect on LDL-cholesterol.23
Antibody-induced inhibition of Pcsk9 binding to Ldlr is currently
investigated as a very promising therapy to reduce plasma
LDL-cholesterol and atherosclerosis in patients.24,25 Our study
demonstrates a Sirt1-dependent alternative route to target Pcsk9 ac-
tivity in amousemodel. Thus, a Sirt1 activator combinedwith a statin
may confer the advantage of lowering plasma Pcsk9 activity. Future
studies are needed to translate the effects of pharmacological Sirt1
activation to patients.
Supplementary material
Supplementary material is available at European Heart Journal online.
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Supplemental Methods 
Cholesterol profiles and lipoprotein fractions 
Cholesterol and triglyceride plasma concentrations were measured using colorimetric and 
enzymatic methods with ready to use kits (BioMérieux). To assess the distribution of 
cholesterol and triglycerides over the different lipoprotein fractions, lipoproteins were 
separated by size exclusion chromatography followed by online determination of lipids.1 
Transfections 
Sirt1 gene silencing in AML12 cells was accomplished by transfecting mouse Sirt1 siRNA 
(Dharmacon) using Lipofectamine (Invitrogen); Scramble siRNA (Microsynth) was used for 
negative control. Sirt1 overexpression was accomplished by transfection of an overexpression 
vector and a scramble empty vector as control (provided by Johan Auwerx) using the Jet Pei 
transfection protocol. 
LDL uptake 
AML12 hepatocytes were incubated with 5 µg/ml  of BODIPY-labelled human LDL (L-
3483, Invitrogen) in 6-well plates in serum-free medium for 1 h at 37 °C. After two washings 
with PBS, uptake of BODIPY-labelled LDL was determined by analysis of fluorescence 
using FacsCanto flow cytometer (BD Bioscience, Heidelberg, Germany), and the percentage 
of positive platelets calculated with FacsDiva software. 
ELISA of plasma cytokines and Pcsk9 
Monocyte chemoattractant protein 1 (Mcp-1) and interleukin 6 (Il-6) plasma levels were 
measured using an adipokine panel kit (Millipore); Pcsk9 was determined by ELISA 
(Circulex, MBL). 
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RNA and protein analyses 
Total RNA was extracted using Trizol (Sigma-Aldrich) and reverse transcribed with random 
hexamers. cDNA obtained was quantified by SYBR-green qPCR using gene-specific 
primers. Results were normalized to Rps29 and Rps18. Total protein from tissues and cells 
was prepared as described and analysed using RIPA lysis buffer and standard protocols.2 
Protein was immunostained using specific antibodies targeted to Sirt1 (Cell signalling), Ldlr 
(Novus Biologicals), Pcsk9 (Abcam) or ß-actin, and detected by horseradish peroxidase 
chemiluminescence. 
Immunoprecipitation 
Foxo1 and p65 acetylation was assessed by immunoprecipitating Foxo1 and p65 from 1 mg 
of total proteins from liver, followed by immunoblotting against acetylated lysine (Abcam), 
anti-acetyl-Foxo1 (Santa Cruz) or anti-acetylK310-p65 (Abcam), respectively. Membranes 
were stripped and reblotted to assess loading with anti-Foxo1 (Santa Cruz) and anti-p65 
(Abcam). 
Immunohistochemistry 
Serial cryosections from the aortic sinus were obtained from frozen tissues fixed in OCT. 
Cryosections were fixed in acetone, blocked in 2% normal mouse serum, and stained with 
oil-red O (ORO), anti-Cd68 (Abcam) and Vcam-1 (Abcam) antibodies. For en face analysis 
of atherosclerotic lesion area thoraco-abdominal aortae were fixed with 4% 
paraformaldehyde and plaques were stained with ORO and analysed as described.3 
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Sirt1 activity assay 
Activation of Sirt1 proteins (wild-type and a Sirt1 activation-resistant mutant (E230K)) was 
measured using the O-Acetyl ADP ribose mass spectrometry assay (OAcADPR assay) as 
described. 4 
49
Miranda et al: The Sirt1 activator SRT3025 increases hepatic Ldlr expression – SOM – R1 5"
Supplemental Table 1: Plasma and tissue levels of SRT3025 in Apoe-/- mice
Tissue HCD HCD+SRT3025 Units
Plasma nd 8.87 ± 2.33 μmol /L
Aortae nd 2.67 ± 3.40 μmol /g 
Liver nd 8.26 ± 5.29 μmol /g 
Plasma and tissue levels of SRT3025. Eight week-old Apoe-/- mice were fed a high-
cholesterol diet (1.25% w/w) supplemented with the Sirt1 activator SRT3025 (n=9) or 
placebo (n=9) for 12 weeks. After this treatment period, mice were sacrificed (after overnight 
fasting), EDTA blood was taken and tissues were harvested. Levels of drug were measured 
by LCMS. nd, not detectable. 
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Supplemental Table 2 
Primers 
Gene Forward Primer Reverse Primer 
Abcg5 AGGGCCTCACATCAACAGAG GCTGACGCTGTAGGACACAT 
Abcg8 TCCGAGGAGAACAAGCTGTC CACTGGTCATGGCTGAGAAA 
Abca1 GCTGCAGGAATCCAGAGAAT CATGCACAAGGTCCTGAGAA 
Ldlr AGTGGCCCCGAATCATTGAC CTAACTAAACACCAGACAGAGGC 
Pcsk9 GAGACCCAGAGGCTACAGATT AATGTACTCCACATGGGGCAA 
Pparα AGAGCCCCATCTGTCCTCTC ACTGGTAGTCTGCAAAACCAAA 
Pparγ TCGCTGATGCACTGCCTATG GAGAGGTCCACAGAGCTGATT 
Lxr CTGATTCTGCAACGGAGTTGT GACGAAGCTCTGTCGGCTC 
Rxr ATGGACACCAAACATTTCCTGC CCAGTGGAGAGCCGATTCC 
Srebp1 TGGTTGTTGATGAGCTGGAG GGCTCTGGAACAGACACTGG 
Srebp2 GCAGCAACGGGACCATTCT CCCCATGACTAAGTCCTTCAACT 
Tnf-α CCCTCACACTCAGATCATCTTCT GCTACGACGTGGGCTACAG 
Mcp-1 TCAGCTGCCTGCAAAGACCAGA ACGGTGTGGTGGCCCCTTCAT 
Il-6 TAGTCCTTCCTACCCCAATTTCC TTGGTCCTTAGCCACTCCTTC 
Rps18 AGTTCCAGCACATTTTGCGAG TCATCCTCCGTGAGTTCTCCA 
Rps29 GTCTGATCCGCAAATACGGG AGCCTATGTCCTTCGCGTACT 
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Supplemental Figures 
Suppl Figure 1. SRT3025 mimics a caloric restriction phenotype in Apoe-/- mice. 
Eight week-old Apoe-/- mice were fed a high-cholesterol diet (1.25% w/w) supplemented with 
the Sirt1 activator SRT3025 (n=9) or placebo (n=9) for 12 weeks. Plasma HDL-cholesterol 
and triglycerides (a); body weight course of Apoe-/- mice fed a HCD without (control) or with 
SRT3025 (S1A) and normalized to initial body weight before diet (b); average daily food 
intake (c) and weight of epididymal white adipose tissue (epiWAT) (d); hepatic enzymes: 
ALP, GOT and GPT (e). HDL, high-density lipoprotein; HCD, high-cholesterol diet; ALP, 
alkaline phosphatase; GOT, glutamic oxaloacetic transaminase; GPT, glutamic pyruvic 
transaminase. 
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Suppl Figure 2. SRT3025 mimics a caloric restriction phenotype in Ldlr-/- mice. 
Eight week-old Ldlr-/- mice were fed a high-cholesterol diet (1.25% w/w) supplemented with 
the Sirt1 activator SRT3025 (n=9) or placebo (n=9) for 12 weeks. Plasma HDL-cholesterol 
and triglycerides (a); body weight course of Ldlr-/- mice fed a HCD without (control) or with 
SRT3025 (S1A) and normalized to initial body weight before diet (b); average daily food 
intake (c) and weight of epididymal white adipose tissue (epiWAT) (d); hepatic gene 
expression of Ldlr-/- control mice and Ldlr-/- mice treated with SRT3025 for 12 weeks (e). 
HDL, high-density lipoprotein; HCD, high-cholesterol diet. 
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!6. Perspectives
“A man is as old as his arteries” 
—Thomas Sydenham, 1624–1689 
6.1 SIRT1 activator SRT3025, atherosclerosis and dyslipidaemia 
Our studies in mice with SRT3025 demonstrate that STACs can reduce 
atherosclerosis by stimulating SIRT1 activity and lowering plasma PCSK9 
levels. Although the study of sirtuins and lipid metabolism is still in its infancy, 
increasing evidence shows that SIRT1 activation improves plasma lipid profile 
in mice and humans, thus creating an opportunity to treat dyslipidaemia. 
Our findings show SRT3025 to be atheroprotective in ApoE-/- mice by 
reducing plasma LDL-cholesterol, highlighting the potential of SIRT1 
activators for prevention or therapy in human cardiovascular disease. In 
addition, SRT3025 was found to reduce hepatic steatosis in diet-induced 
obese mice through a suppression of lipogenesis and an increase in fatty acid 
oxidation (Abstract, Qing Nie), further underlining the therapeutic potential of 
STACs. However, despite the fact that SRT3025 showed promising 
atheroprotective effects in mice, pharmacokinetic and safety studies of 
SRT3025 in humans showed a dose-dependent QTc prolongation (Jonathan 
Haddad, 2013). Thus, SRT3025 itself could not be pursued in human studies 
but provides evidence that SIRT1 activation would be an interesting target 
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!against atherosclerosis. Clinical trials of another SIRT1 activator – SRT2104 
administered to elderly volunteers and healthy cigarette smokers also showed 
reductions of plasma total cholesterol and LDL-cholesterol levels. Consistent 
with this, we found that SIRT1 activation by SRT3025 reduces plasma LDL-
cholesterol in ApoE-/- mice by reducing the secretion of PCSK9 in the plasma 
and increasing hepatic LDL-R expression. An increase in LDL-R causes an 
increase in LDL-cholesterol uptake leading to reduction in plasma LDL-
cholesterol. Although the effect of SRT3025 was shown to be SIRT1-
dependent, further investigation is required to understand the mechanism for 
the reduction in PCSK9 secretion. Furthermore, the plasma PCSK9 levels of 
patients receiving SIRT1 activators still need to be investigated. 
6.2 Role of sirtuins in the regulation of PCSK9 
Although these findings support the notion that SIRT1 activation reduces 
PCSK9 secretion, direct interaction of SIRT1 and PCSK9 has yet to be 
investigated. It is appealing to postulate that SIRT1 may directly deacetylate 
PCSK9. If SIRT1, indeed, deacetylates PCSK9, it would be informative to 
assess the difference in acetylation status of PCSK9 in diseased patients as a 
surrogate not only for SIRT1 activity but also for PCSK9 activity. Recently, it 
was shown that PCSK9 expression could also be regulated by SIRT6.87 Such 
findings confirm that sirtuins indeed play an important role in PCSK9-mediated 
LDL-cholesterol regulation, which occurs both at a transcriptional and post-
translational level. Since knockdown of SIRT1 blocks SIRT6 induction in 
hepatocytes, it can be postulated that absence of SIRT1 may cause a 
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!reduction in PCSK9 regulation transcriptionally, rather than post-
translationally. Further studies need to be done to assess whether other 
sirtuins regulate PCSK9 expression and to determine whether there is any 
cross talk between SIRT1 and SIRT6 in regulating plasma PCSK9 levels. 
6.3 SIRT1, white adipose tissue and atherosclerosis 
Subcutaneous white adipose tissue is known to be an active immune organ 
that stores excess calories from circulating lipids in adipocytes and secretes 
inflammatory adipokines and hormones. Adipocytes can secrete a number of 
pro-inflammatory adipokines, such as MCP-1 and IL-6.88 SIRT1 is known to 
modulate proliferation and inflammation in adipose tissue by repressing 
adipocyte differentiation and macrophage infiltration.89 In our experimental 
models of atherosclerosis, both ApoE-/- and LDL-R-/- mice treated with the 
SIRT1 activator, SRT3025, showed a reduction in circulating MCP-1 and IL-6. 
In line with this, the reduction in systemic cytokines corresponded to the 
reduced mass of subcutaneous white adipose tissue in both models. Thus it 
can be suggested that the reduction in subcutaneous WAT is associated with 
the reduction in inflammation. It would be interesting to assess if the reduction 
in inflammation and inflammatory cytokines are causatively related to SIRT1 
activity on white adipose tissue mass and if this can be linked to obesity. 
Obesity is known to cause insulin resistance, an enlargement of 
adipocytes and accumulation of lipids within adipocytes. SIRT1 is known to 
improve insulin sensitivity and protect against obesity by reducing adipocyte 
proliferation.90 However, the relationship between obesity and cardiovascular 
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!disease has been controversial at best. Results from the ‘Seven Countries 
Studies' epidemiological study showed that there was little relationship 
between body weight and coronary artery disease.91 It however showed a 
strong association between blood cholesterol levels and coronary artery 
disease. Furthermore, in a major autopsy study called ‘The Geographic 
Pathology of Atherosclerosis’ in which autopsies from Africans were 
compared with New Yorkers, the authors concluded that obesity had little 
relationship with atherosclerosis and that serum lipid content may be more 
important.92 However, it was the ‘Framingham heart study’ that associated the 
risk of atherosclerosis to increasing degrees of obesity.93 Although all 
epidemiological studies had shortcomings on the design of their studies, many 
critics of the Framingham heart study claimed that the risks were related to 
major risk factors like cholesterol, blood pressure and diabetes and not 
obesity itself. In line with this, in our study we found no change in 
atherosclerosis in LDL-R-/- mice, although body weight was decreased. In 
ApoE-/- mice treated with SRT3025, plasma LDL-cholesterol and total 
cholesterol were lower and were associated with to the reduced WAT mass 
and inflammatory cytokines phenotype; however, in LDL-R-/- mice treated with 
the same drug, plasma LDL-cholesterol and total cholesterol was not 
associated with the reduced levels of WAT mass and inflammatory cytokines. 
If obesity indeed were a direct risk factor of atherosclerosis in mice, the 
reduction of body weight and fat in LDL-R-/- mice would be atheroprotective, 
which was not the case. Our study further shows that atherosclerosis in mice 
was primarily due to altered levels of only one major risk factor – LDL-
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!cholesterol, and not body-weight, fat mass or inflammation in the mice. 
Further studies of atherosclerosis in an obese mouse model lacking LDL-R or 
ApoE would help prove that atherosclerosis may be prevented by only 
reducing LDL-cholesterol and is independent of obesity or inflammation. 
Since atherosclerosis is a chronic inflammatory disease triggered by 
elevated levels of LDL-cholesterol, a lot of research has focused on 
inflammation and inflammatory markers as prognostic biomarkers for the 
progression or risk of atherosclerosis. Our findings show that inflammation 
during atherosclerosis could be a secondary effect, independent of plasma 
LDL-cholesterol levels. Comparison of all inflammatory markers in the plasma 
of ApoE-/- mice and LDL-R-/- mice treated with SRT3025 by proteomics would 
reveal novel causative inflammatory biomarkers of atherosclerosis which 
could be used in prognosis of the disease. These inflammatory biomarkers 
would be more closely associated with plasma lipid content rather than 
systemic inflammation. Such a strategy would also provide biomarkers 
independent of those secreted by white adipose tissue and directly related to 
SIRT1 activity. Given the reduction in WAT in both models, the cytokines 
released from WAT such as IL-6 and MCP-1 may also prove to be of less 
importance in the search for biomarkers of atherosclerosis. 
6.4 Alternative pathways of SIRT1 activation: increasing NAD+ levels 
The expression and activity of SIRT1 is dependent on the intracellular 
availability of its substrate NAD+. Thus modulation of intracellular NAD+ levels 
could be another method to increase SIRT1 activity and mimic its beneficial 
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!effects. This can be achieved by two different strategies – increasing NAD+ 
biosynthesis or decreasing NAD+ consumption. During the biosynthesis of 
NAD+ within cells, the enzyme nicotinamide phosphoribosyltransferase 
(NAMPT) catalyses the rate limiting step of converting nicotinamide to 
nicotinamide mononucleotide (NMN) and pyrophosphate.94 NMN is then 
converted to NAD+ by the isoenzyme nicotinamide mononucleotide 
adenylyltransferase. 
The physiological role of NAD+ biosynthesis is well understood, 
however its role in diseases is yet unclear. Extracellular NAMPT has been 
shown to behave as an insulin-mimetic and an inflammatory cytokine.95, 96 
Thus, pharmacological activation of NAMPT may not be an attractive strategy 
to increase NAD+ levels and SIRT1 activity. Supplementation with NMN was 
shown to protect mice hearts from ischemia-reperfusion injury by increasing 
SIRT1 activity and upregulating NAMPT levels. These protective effects were 
lost in cardiac-specific SIRT1 knockout mice, thus providing evidence that 
exogenous supplementation with NMN may be used to increase NAD+ levels 
and activate SIRT1. Currently few studies have addressed the modulation of 
NAD+ levels by supplementation of tryptophan and nicotinic acid (NA). 
Tryptophan is the main precursor required for the de novo biosynthesis of 
NAD+, while nicotinic acid is another NAD+ precursor required by the Preiss-
Handler pathway. Dietary supplementation of both precursors in animals are 
known to increase intracellular levels of the precursor and thus cellular NAD+ 
levels.97 98 Bioavailability of NAD+ is critical for normal cellular functions, thus 
cells can also retrieve NAD+ through the salvage pathway.  
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!Figure 8. Modulation of NAD+ biosynthesis and consumption. Since 
activity of SIRT1 depends on the availability of NAD+ in the cells, different 
strategies can be employed to increase cellular NAD+. Intracellular NAD+ 
biosynthesis can be increased by supplementation with NAD+ precursors like 
nicotinic acid (NA), nicotinamide ribose (NR), nicotinamide mononucleotide 
(NMN) and tryptophan. The consumption of NAD+ can be reduced by 
inhibition of NAD+ consuming enzymes such as poly (ADP-ribose) polymerase 
(PARP) and CD38. 
The main precursors for the salvage pathway are nicotinic acid, 
nicotinamide (NAM) and nicotinamide riboside (NR). Since NA and NAM have 
comparative metabolism in mice, both can lead to higher levels of NAD+ in 
NAD+ consumption
NAD+ biosynthesis
PARPs% CD38%
NAD+%
NA%
NR% NMN%
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!tissues, which may also be tissue-specific.99 NAM seems to be a more stable 
precursor of NAD+ in the liver, NA in the kidney and NR in neurons.99-101 While 
the effects of NA and NAM have been studied through niacin, the function of 
NR has yet to be investigated. Niacin, a vitamin mainly composed of NA and 
NAM is used to treat hypercholesterolemia as it has beneficial effects on lipid 
metabolism. Niacin decreases VLDL-cholesterol and plasma LDL-cholesterol 
levels and increases plasma HDL-cholesterol levels. 102, 103 It is not yet known 
whether these beneficial effects are due to SIRT1 activation. However, similar 
to SIRT1, niacin increases HDL-cholesterol levels through an increase in 
ABCA1 expression. Since niacin has already been established as a lipid-
lowering agent, the question remains whether more specific activators of 
NAD+ biosynthesis cause further lowering of plasma cholesterol.  
Another approach to increase SIRT1 activity through NAD+ levels is by 
decreasing the consumption of NAD+ within cells. Poly ADP-ribose 
polymerase (PARP) and CD38 are two enzymes that utilize NAD+ as a 
substrate for their cellular processes. While PARP utilizes NAD+ to build ADP-
ribose polymers, CD38 uses NAD+ to increase secondary messengers, mainly 
cADP-ribose.104, 105 Loss of PARP-1 in ApoE-/- mice can protect against 
vascular dysfunction through an increase in eNOS activity.106, 107 Currently 
PARP inhibitors are being investigated in a clinical setting for the treatment of 
cancer due to their role in DNA damage and apoptosis. Although inhibition of 
PARPs and CD38 has been shown to increase NAD+ levels,108, 109 further 
studies are required to assess if these inhibitors can provide beneficial effects 
in a clinical setting through SIRT1. 
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!6.5 Future prospects 
SIRT1 activation itself is a promising concept but the road from bench to 
bedside for drugs may be long and tedious. There are many obstacles and 
checkpoints for SIRT1 activators to pass before they can be used in the 
treatment of human diseases. Given the various target substrates of SIRT1, 
the differential deacetylation of SIRT1 substrates by STACs, their potential off-
target effects and the various pathways involved in different diseases, it will be 
a challenge to establish the therapeutic potential of the currently approved 
SIRT1 activators. 
Future studies on the mechanism and specificity of SIRT1 activation 
will support the discovery of novel drugs that could activate SIRT1 and exhibit 
target specificity. These premises may allow them to be tested for 
atheroprotection in patients. 
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